Post Profile

A furious employee is suing drugmaker Mallinckrodt over claims about its $38,000-a-dose blockbuster

The legal challenges at Mallinckrodt, the drugmaker Wall Street loves to hate, are piling up. An employee of the company is suing the company and its leadership, alleging they lied about its dependence on its controversial blockbuster drug, Acthar. The employee bought shares as part of the company's stock purchase plan, so he's also suing on behalf of the plan. The complaint is that Mallinckrodt's failure to disclose that up to 60% of Acthar's revenue comes from Medicare and Medicaid put its revenues at greater risk than management led on.
read more


Related Posts

Something weird's going on with the doctors prescribing one of pharma’s most controversial blockbuster drugs (MNK)

Business & Finance : Business Insider: Money Game

The effectiveness of Mallinckrodt Pharmaceuticals' blockbuster drug H.P. Acthar over cheaper alternatives is being questioned by an Oregon State University study. The drug is prescribed by a small number of doctors, and many of them...

An Illinois city just stepped into the war against big pharma over drug pricing

Business & Finance : Business Insider: Money Game

Rockford, Illinois, is suing Mallinckrodt Pharmaceuticals over the price of one of the company's blockbuster drugs, Acthar. Rockford is accusing Mallinckrodt of taking advantage of its hold on the market and charging an exorbitant p...

Check out how the shorts have been piling into Wall Street's most hated pharma stock (MNK)

Business & Finance : Business Insider: Clusterstock

Over the last couple of months, Wall Street short sellers have been piling into a drug company called Mallinckrodt Pharmaceuticals. Short sellers bet that a stock will fall. To do so they have to borrow shares from other holders in ...

A Wall Street investor call revealed part of the secret of why drugs are so expensive (MNK, ESRX)

Business & Finance : Business Insider: Money Game

Mallinckrodt Pharmaceuticals is facing scrutiny over the price of its blockbuster drug Acthar, some say it wouldn't be viable without an opaque distribution system. The company depends on pharmacy-benefit manager (PBM) Express Scrip...

One of Wall Street's most hated drug makers is tanking after getting bashed by an ally

Business & Finance : Business Insider: Clusterstock

Mallinckrodt Pharmaceuticals is getting crushed after executives at one of its key distributors were cited bashing the company's blockbuster drug. The comments were made by senior executives at Express Scripts, which distributes Mal...


Copyright © 2016 Regator, LLC